Update of NIOSH Nanotechnology Strategic Plan for Research and Guidance, 4150-4151 [2013-00994]

Download as PDF 4150 Federal Register / Vol. 78, No. 13 / Friday, January 18, 2013 / Notices Number of respondents Type of respondent Form name Master of a vessel or person in charge of a conveyance. 42 CFR 70.4 Report by the master of a vessel or person in charge of conveyance of the incidence of a communicable disease occurring while in interstate travel (Paper Form if requested by CDC during public health emergency). 42 CFR 70.4 Copy of material submitted to state or local health authority under this provision (Paper Form if requested by CDC during public health emergency). 42 CFR 70.4 Report by the master of a vessel or person in charge of conveyance of the incidence of a communicable disease occurring while in interstate travel (Radio or other telecommunication for routine reporting). 42 CFR 70.4 Copy of material submitted to state or local health authority under this provision (Radio or other telecommunication for routine reporting). 42 CFR 70.5 Application for a permit to move from State to State while in the communicable period. 42 CFR 70.5 Application for a permit to move from State to State while in the communicable period. State health authority ....................... Master of a vessel or person in charge of a conveyance. State health authority ....................... Traveler ............................................ Attending physician .......................... Dated: January 10, 2013. Ron A. Otten, Director, Office of Scientific Integrity (OSI), Office of the Associate Director for Science (OADS), Office of the Director Centers for Disease Control and Prevention. [FR Doc. 2013–00987 Filed 1–17–13; 8:45 am] BILLING CODE 4163–18–P Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Dated: January 11, 2013. John Kastenbauer, J.D., Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2013–00989 Filed 1–17–13; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4163–18–P Centers for Disease Control and Prevention DEPARTMENT OF HEALTH AND HUMAN SERVICES Office for State, Tribal, Local and Territorial Support (OSTLTS) Meeting; Correction Centers for Disease Control and Prevention This document corrects a notice that was published in the Federal Register on January 7, 2013 (78 FR 949– 950). The 10th Biannual Tribal Consultation session has been postponed to coincide with the summer 2013 meetings; the dates will be announced once they are determined. The Tribal Advisory Committee Meeting will be extended and held February 5, 6, and 7, 2013, from 8:00 a.m.–4:30 p.m. FOR FURTHER INFORMATION CONTACT: Kimberly Cantrell, Deputy Associate Director for Tribal Support, OSTLTS, via mail to 4770 Buford Highway NE., MS E–70, Atlanta, Georgia 30341 or email to klw6@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Update of NIOSH Nanotechnology Strategic Plan for Research and Guidance mstockstill on DSK4VPTVN1PROD with SUMMARY: VerDate Mar<15>2010 16:52 Jan 17, 2013 Jkt 229001 [CDC–2013–0001; NIOSH–134–B] National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Request for Information: Update of NIOSH Nanotechnology Strategic Plan for Research and Guidance. AGENCY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) seeks comment on the types of hazard identification and risk management research that should be considered for updating the NIOSH FY2013–FY2016 nanotechnology strategic plan. This draft strategic plan (Protecting the SUMMARY: PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 Number of responses per respondent Average burden per response (in hours) 1,500 1 15/60 20 75 6/60 200 1 15/60 200 1 15/60 3,750 1 15/60 3,750 1 15/60 Nanotechnology Workforce: NIOSH Nanotechnology Research and Guidance Strategic Plan 2013–2016) can be found in Docket CDC–2013–0001 at http://www.regulations.gov. DATES: Comments must be received March 19, 2013. ADDRESSES: You may submit comments, identified by CDC–2013–0001 and Docket Number NIOSH–134–B, by either of the two following methods: • Federal erulemaking portal: http:// www.regulations.gov. Follow the instructions for submitting comments. • Mail: NIOSH Docket Office, Robert A. Taft Laboratories, MS–C34, 4676 Columbia Parkway, Cincinnati, OH 45226. Instructions: All information received in response to this notice must include the agency name and docket number (CDC–2013–0001; NIOSH–134–B). All relevant comments received will be posted without change to http:// www.regulations.gov, including any personal information provided. For access to prior background documents or previous comments received, go to http://www.cdc.gov/niosh/docket/ archive/docket134.html and http:// www.cdc.gov/niosh/docket/archive/ docket134A.html. FOR FURTHER INFORMATION CONTACT: Charles L. Geraci, NIOSH, Robert A. Taft Laboratories, MS–C14, 4676 Columbia Parkway, Cincinnati, Ohio 45226, telephone (513) 533–8339. SUPPLEMENTARY INFORMATION: Background Since 2004, the National Institute for Occupational Safety and Health E:\FR\FM\18JAN1.SGM 18JAN1 mstockstill on DSK4VPTVN1PROD with Federal Register / Vol. 78, No. 13 / Friday, January 18, 2013 / Notices (NIOSH) of the Centers for Disease Control and Prevention (CDC) has pioneered research on the toxicological properties and characteristics of nanoparticles. This research has involved characterizing occupationally relevant nanoparticles for predicting whether these particles pose a risk of adverse health effects and for providing guidance on controlling workplace exposures. In September 2005, NIOSH developed a strategic plan to further guide the Institute in identifying and prioritizing nanotechnology research. In 2009 this strategic plan [http:// www.cdc.gov/niosh/docs/2010-105] was updated based on knowledge gained from results of ongoing NIOSH research [see Progress Toward Safe Nanotechnology in the Workplace; A Report from the NIOSH Nanotechnology Research Center http://www.cdc.gov/ niosh/docs/2007-123/] and from the public and stakeholder input. NIOSH would like to build on the accomplishments of ongoing research [http://www.cdc.gov/niosh/docs/2013101/ and http://www.cdc.gov/niosh/ docs/2010-104/] to develop strategic research goals and objectives for nanotechnology occupational safety and health research through 2016. NIOSH has identified 10 critical research areas for nanotechnology research and communication. These 10 critical research areas are (1) Toxicity and internal dose, (2) measurement methods, (3) exposure assessment, (4) epidemiology and surveillance, (5) risk assessment, (6) engineering controls and personal protective equipment (PPE), (7) fire and explosion safety, (8) recommendations and guidance, (9) global collaborations, and (10) applications. NIOSH is considering focusing the overarching strategic research goals for these critical areas on 5 key objectives: (1) Increase understanding of new hazards and related health risks to nanomaterial workers; (2) Expand understanding of the initial hazard findings on engineered nanomaterials; (3) Support the creation of guidance materials to inform nanomaterial workers, employers, health professionals, regulatory agencies, and decision-makers about hazards, risks, and risk management approaches; (4) Support epidemiologic studies for nanomaterial workers, including medical and exposure studies; and 5) Assess and promote national adherence with risk management guidance. NIOSH requests public input to address the following: (1) What is the basis or rationale for priorities that NIOSH should give for studies of toxicity evaluation and/or VerDate Mar<15>2010 16:52 Jan 17, 2013 Jkt 229001 workplace exposure characterization for engineered nanoparticles? (2) What rationale can be provided for recommending needs and types of technical and educational guidance materials? Dated: January 14, 2013. John Howard, Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. [FR Doc. 2013–00994 Filed 1–17–13; 8:45 am] BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–3278–N] Medicare Program; Request for Information on Hospital and Vendor Readiness for Electronic Health Records Hospital Inpatient Quality Data Reporting; Extension of Comment Period Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Request for information; extension of the comment period. AGENCY: This notice extends the comment period for a request for information (RFI) which was published in the January 3, 2013 Federal Register (78 FR 308). The RFI requests that hospitals, electronic health record (EHR) vendors, and other interested parties respond to questions regarding their readiness to conduct electronic reporting of certain patient-level data under the Hospital Inpatient Quality Reporting (IQR) Program using the Quality Reporting Document Architecture (QRDA) Category I. The comment period for the RFI, which would have ended on January 22, 2013, is extended to February 1, 2013. DATES: The comment period for the request for information published in the January 3, 2013 Federal Register (78 FR 308) is extended to February 1, 2013. ADDRESSES: In commenting, please refer to file code CMS–3278–NC. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission. You may submit comments in one of four ways (please choose only one of the ways listed): 1. Electronically. You may submit electronic comments on this regulation to http://www.regulations.gov. Follow the instructions under the ‘‘More Search Options’’ tab. SUMMARY: PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 4151 2. By regular mail. You may mail written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–3278–NC, P.O. Box 8013, Baltimore, MD 21244–8013. Please allow sufficient time for mailed comments to be received before the close of the comment period. 3. By express or overnight mail. You may send written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–3278–NC, Mail Stop C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850. 4. By hand or courier. If you prefer, you may deliver (by hand or courier) your written comments before the close of the comment period to either of the following addresses: a. For delivery in Washington, DC— Centers for Medicare & Medicaid Services, Department of Health and Human Services, Room 445–G, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201. (Because access to the interior of the Hubert H. Humphrey Building is not readily available to persons without Federal government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of the building. A stamp-in clock is available for persons wishing to retain a proof of filing by stamping in and retaining an extra copy of the comments being filed.) b. For delivery in Baltimore, MD— Centers for Medicare & Medicaid Services, Department of Health and Human Services, 7500 Security Boulevard, Baltimore, MD 21244–1850. If you intend to deliver your comments to the Baltimore address, please call telephone number (410) 786– 9994 in advance to schedule your arrival with one of our staff members. Comments mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received after the comment period. Submission of comments on paperwork requirements. You may submit comments on this document’s paperwork requirements by following the instructions at the end of the ‘‘Collection of Information Requirements’’ section in this document. For information on viewing public comments, see the beginning of the SUPPLEMENTARY INFORMATION section. FOR FURTHER INFORMATION CONTACT: Maria Harr, (410) 789–6710. E:\FR\FM\18JAN1.SGM 18JAN1

Agencies

[Federal Register Volume 78, Number 13 (Friday, January 18, 2013)]
[Notices]
[Pages 4150-4151]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-00994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CDC-2013-0001; NIOSH-134-B]


Update of NIOSH Nanotechnology Strategic Plan for Research and 
Guidance

AGENCY: National Institute for Occupational Safety and Health (NIOSH) 
of the Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Request for Information: Update of NIOSH Nanotechnology 
Strategic Plan for Research and Guidance.

-----------------------------------------------------------------------

SUMMARY: The National Institute for Occupational Safety and Health 
(NIOSH) of the Centers for Disease Control and Prevention (CDC) seeks 
comment on the types of hazard identification and risk management 
research that should be considered for updating the NIOSH FY2013-FY2016 
nanotechnology strategic plan. This draft strategic plan (Protecting 
the Nanotechnology Workforce: NIOSH Nanotechnology Research and 
Guidance Strategic Plan 2013-2016) can be found in Docket CDC-2013-0001 
at http://www.regulations.gov.

DATES: Comments must be received March 19, 2013.

ADDRESSES: You may submit comments, identified by CDC-2013-0001 and 
Docket Number NIOSH-134-B, by either of the two following methods:
     Federal erulemaking portal: http://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: NIOSH Docket Office, Robert A. Taft Laboratories, 
MS-C34, 4676 Columbia Parkway, Cincinnati, OH 45226.
    Instructions: All information received in response to this notice 
must include the agency name and docket number (CDC-2013-0001; NIOSH-
134-B). All relevant comments received will be posted without change to 
http://www.regulations.gov, including any personal information 
provided. For access to prior background documents or previous comments 
received, go to http://www.cdc.gov/niosh/docket/archive/docket134.html 
and http://www.cdc.gov/niosh/docket/archive/docket134A.html.

FOR FURTHER INFORMATION CONTACT: Charles L. Geraci, NIOSH, Robert A. 
Taft Laboratories, MS-C14, 4676 Columbia Parkway, Cincinnati, Ohio 
45226, telephone (513) 533-8339.

SUPPLEMENTARY INFORMATION:

Background

    Since 2004, the National Institute for Occupational Safety and 
Health

[[Page 4151]]

(NIOSH) of the Centers for Disease Control and Prevention (CDC) has 
pioneered research on the toxicological properties and characteristics 
of nanoparticles. This research has involved characterizing 
occupationally relevant nanoparticles for predicting whether these 
particles pose a risk of adverse health effects and for providing 
guidance on controlling workplace exposures. In September 2005, NIOSH 
developed a strategic plan to further guide the Institute in 
identifying and prioritizing nanotechnology research. In 2009 this 
strategic plan [http://www.cdc.gov/niosh/docs/2010-105] was updated 
based on knowledge gained from results of ongoing NIOSH research [see 
Progress Toward Safe Nanotechnology in the Workplace; A Report from the 
NIOSH Nanotechnology Research Center http://www.cdc.gov/niosh/docs/2007-123/] and from the public and stakeholder input. NIOSH would like 
to build on the accomplishments of ongoing research [http://www.cdc.gov/niosh/docs/2013-101/ and http://www.cdc.gov/niosh/docs/2010-104/] to develop strategic research goals and objectives for 
nanotechnology occupational safety and health research through 2016. 
NIOSH has identified 10 critical research areas for nanotechnology 
research and communication. These 10 critical research areas are (1) 
Toxicity and internal dose, (2) measurement methods, (3) exposure 
assessment, (4) epidemiology and surveillance, (5) risk assessment, (6) 
engineering controls and personal protective equipment (PPE), (7) fire 
and explosion safety, (8) recommendations and guidance, (9) global 
collaborations, and (10) applications.
    NIOSH is considering focusing the overarching strategic research 
goals for these critical areas on 5 key objectives: (1) Increase 
understanding of new hazards and related health risks to nanomaterial 
workers; (2) Expand understanding of the initial hazard findings on 
engineered nanomaterials; (3) Support the creation of guidance 
materials to inform nanomaterial workers, employers, health 
professionals, regulatory agencies, and decision-makers about hazards, 
risks, and risk management approaches; (4) Support epidemiologic 
studies for nanomaterial workers, including medical and exposure 
studies; and 5) Assess and promote national adherence with risk 
management guidance.
    NIOSH requests public input to address the following:
    (1) What is the basis or rationale for priorities that NIOSH should 
give for studies of toxicity evaluation and/or workplace exposure 
characterization for engineered nanoparticles?
    (2) What rationale can be provided for recommending needs and types 
of technical and educational guidance materials?

    Dated: January 14, 2013.
John Howard,
Director, National Institute for Occupational Safety and Health, 
Centers for Disease Control and Prevention.
[FR Doc. 2013-00994 Filed 1-17-13; 8:45 am]
BILLING CODE 4163-19-P